AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

The global amyotrophic lateral sclerosis (ALS) market is estimated to be valued at USD 1,818.0 Mn in 2026 and is expected to reach USD 3,986.1 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 11.9% from 2026 to 2033. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive and fatal neurodegenerative disease characterized by degeneration and death of the upper and lower motor neurons that control voluntary muscle movements. ALS patients develop muscle weakness, stiffness, twitching and difficulty with talking, swallowing and breathing, eventually resulting in paralysis and respiratory failure. ALS is more common in males and affects mainly the age group of 40-70 years with 5-10% of cases being familial and the rest sporadic.

The global amyotrophic lateral sclerosis (ALS) market includes therapeutics, diagnostics, assistive technologies, and new pipeline therapies that seek to slow the disease progression and alleviate its symptoms. The market is gaining traction because of increased disease awareness, increased research funding, and advancements in drug development that are driving innovation and generating interest from pharmaceutical companies, biotechnology companies, and healthcare stakeholders.

Market Dynamics

The global amyotrophic lateral sclerosis (ALS) market is driven by increasing patient population, rising disease awareness, and increasing diagnosis and treatment. The availability of therapies like riluzole and edaravone, and the emergence of targeted therapies like tofersen for SOD1 associated ALS, are encouraging investments in ALS research.

However, the growth of amyotrophic lateral sclerosis (ALS) market is limited by factors such as high costs of treatment, limited reimbursement in developing economies, complex disease biology and high clinical trial failure rates. Nevertheless, advances in genetic research involving ALS-associated mutations such as SOD1, C9orf72, TARDBP, and FUS are supporting precision medicine development, while collaborations between biotechnology companies and academic institutions and expedited regulatory pathways are accelerating the development of promising therapies.

Key Features of the Study

• This report provides in-depth analysis of the global amyotrophic lateral sclerosis (ALS) market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global amyotrophic lateral sclerosis (ALS) market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen Inc., Mitsubishi Tanabe Pharma Corporation, Sanofi. Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Ionis Pharmaceuticals, Inc., AB Science, BrainStorm Cell Therapeutics Inc., Clene Inc., and Sun Pharmaceutical Industries Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global amyotrophic lateral sclerosis (ALS) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global amyotrophic lateral sclerosis (ALS) market

Market Segmentation

• Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
  • Sodium Phenylbutyrate and Taurursodiol
  • Edaravone
  • Nuedexta
  • Tofersen
  • Riluzole
  • Muscle Relaxants
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Others
• Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
  • Oral
  • Parenteral
  • Others
• Dosage Form Insights (Revenue, USD Mn, 2021 - 2033)
  • Oral Suspension
  • Injectable
  • Tablets
  • Others
• Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Biogen Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Sanofi
  • Otsuka Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • Ionis Pharmaceuticals, Inc.
  • AB Science
  • BrainStorm Cell Therapeutics Inc.
  • Clene Inc.
  • Sun Pharmaceutical Industries Limited